Abivax stock jumps on positive Phase 3 ulcerative colitis data
Seeking Alpha ·
Abivax SA ( ABVX ) shares surged Tuesday premarket after the biotech reported positive topline supplemental data from its Phase 3 ulcerative colitis maintenance program, delivering strong efficacy while easing long-term safety and cancer concerns ahead of its planned NDA submission.
DYAX Investor Sentiment
Bullish (Long) 30% · Bearish (Short) 70%
365 participants
Related News
- Palantir Stock vs. Sandisk Stock: Wall Street Says Buy One and Sell the Other
- EchoStar's Dish DBS set to file for bankruptcy - report
- Apple launching updates early amid AI cybersecurity concerns: report
- Wolfson Group Acquires Portfolio of Wellness Brands to Accelerate U.S. Expansion
- Nasdaq, S&P 500, Dow Futures Hold Steady Ahead Of JOLTS Report, Nike Earnings: Why SLS, TSLA, SPCX, SNDK, AVAV, JACK Are In Focus
- UK watchdog proposes changes to Apple and Google’s app stores payment rules